1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012;57:167–85
  2. Marcellin P, Buti M, Gane E, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013;58(Suppl 1):649A. Abstract 926
  3. Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load (≥ 9 log10 copies/mL). Hepatology 2013;58:505-513
  4. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75
  5. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
  6. Lampertico P, Soffredini R, Yurdaydin C, et al. Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favourable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Hepaology 2013;58(Suppl1):653A. Abstract 933
  7. Petersen J, Heyne R, Mauss S, et al. Effectiveness of tenofovir for chronic hepatitis B in field practice - 2 year interim results from the prospective German multicenter non-interventional study (GEMINIS). EASL 2013 Abstract 768
  8. Hézode C, Causse X, Larrey D, et al. Virological response and tolerance of tenofovir DF (TDF) in the elderly is similar to younger patients in real life practice. EASL 2013 Abstract 748
  9. Van Bommel F, Zoutendijk R, de Man R, et al. A European field study of the efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in patients with prior failure to other nucleoside/nucleotide analogues. J Hepatol 2012;56;S216
  10. Lampertico P, Soffredini R, Viganò M et al. Tenofovir monotherapy suppressed viral replication in most field practice, treatment-naïve ­­patients with CHB followed for 3 years in a multicenter European study. Hepatology 2012;56(Suppl 1):Abstract 401
  11. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014;146(4):980-988
  12. Berg T, Zoulim F, Moeller B, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014;60(4):715-22
  13. Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 2013;28(6):912-23
  14. Hall AM, Hendry BM, Nitsch D, Connoly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of evidence. Am J Kudney Dis 2011;57:773-80
  15. Fung S, Kwan P, Horban A, et al. Tenofovir DF (TDF) is safe and well tolerated in chronic hepatitis B (CHB) patients with pre-existing mild renal impairment. EASL 2013 Abstract 744
  16. Carey I, Knighton S, Bruce M et al. Switch from long-term de-novo lamivudine+adefovir therapy to tenofovir or/and entecavir improves viral response and renal/bone safety EASL 2013. Abstract 738
  17. Lampertico P, Mangia G, Viganò M, et al. Tenofovir monotherapy is effective for adefovir experienced patients but requires careful monitoring of glomerular and tubular function and proactive dose reductions: a 4-years study in 320 patients. Hepatology 2013;58(Suppl 1):649A. Abstract 927
  18. Viganò M, Lampertico P, Soffredini R, et al. Switching to tenofovir is safe in most chronic hepatitis B patients with a reduced glomerular filtration rate due to previous exposure to adefovir dipivoxil AASLD 2012 Abstract 406
© Effetti srl